Brief: Braxia Scientific Reports Q3 2022 Financial Results
01/03/2022 22:34
March 1 (Reuters) - Braxia Scientific Corp BRAX.CD :
* BRAXIA SCIENTIFIC REPORTS Q3 2022 FINANCIAL RESULTS;
COMPANY
LEADS IN PSYCHEDELIC RESEARCH, ACCESS AND THERAPIST TRAINING
WITH FIRST MULTI-DOSE PSILOCYBIN TRIAL IN CANADA
* Q3 REVENUE ROSE 13.3 PERCENT TO $324,900
Source text for Eikon: ID:nCNWf05Pqa
Further company coverage: BRAX.CD
Recent news on Braxia Scientific
See all newsBrief: Braxia Scientific Reports Q3 2022 Financial Results
Brief: Braxia Scientific CEO Roger Mcintyre To Join Advisory Board Of At-Home Telemedicine Platform KetaMD
Brief: Braxia Scientific To Commence Canada's First Multiple-Dose Psilocybin Trial For Treatment Resistant Depression
Brief: Braxia Scientific Launches Psilocybin-Assisted Clinical Therapy Training Program
Brief: Braxia Scientific Awarded Government Of Canada Funding To Complete First Of Its Kind Ketamine Clinical Trial For Bipolar Depression